🔬 Deciphering the Future of RCC Treatment: Prof. Manuela Schmidinger on LITESPARK Studies and HIF-2α Inhibitors
At the recent European Society for Medical Oncology (ESMO) conference, a critical spotlight was on the groundbreaking results of the LITESPARK-003 and LITESPARK-005 studies. Understanding the implications of these studies…
